| __timestamp | Ligand Pharmaceuticals Incorporated | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 1860000 |
| Thursday, January 1, 2015 | 24378000 | 2963000 |
| Friday, January 1, 2016 | 26621000 | 6961000 |
| Sunday, January 1, 2017 | 28653000 | 11779000 |
| Monday, January 1, 2018 | 37734000 | 13697000 |
| Tuesday, January 1, 2019 | 41884000 | 15749000 |
| Wednesday, January 1, 2020 | 64435000 | 18638000 |
| Friday, January 1, 2021 | 57483000 | 27196000 |
| Saturday, January 1, 2022 | 70062000 | 31739000 |
| Sunday, January 1, 2023 | 52790000 | 33491000 |
Infusing magic into the data realm
In the competitive world of biotechnology, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, Ligand Pharmaceuticals Incorporated and Protagonist Therapeutics, Inc. have demonstrated distinct approaches to their Selling, General, and Administrative (SG&A) expenses.
Ligand Pharmaceuticals, a seasoned player, has seen its SG&A expenses grow by approximately 133% from 2014 to 2023, peaking in 2022. This reflects a strategic investment in maintaining its market position and expanding its operational capabilities. In contrast, Protagonist Therapeutics, a relatively newer entrant, has shown a staggering increase of over 1,700% in the same period, indicating aggressive growth and expansion efforts.
These trends highlight the dynamic nature of the biotech industry, where companies must balance innovation with operational efficiency to thrive.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Protagonist Therapeutics, Inc.
Amgen Inc. and Protagonist Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Protagonist Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Biogen Inc. and Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Genmab A/S and Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Alpine Immune Sciences, Inc. or Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Xenon Pharmaceuticals Inc. vs Protagonist Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Amicus Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Protagonist Therapeutics, Inc. or Agios Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Protagonist Therapeutics, Inc. vs Evotec SE: SG&A Expense Trends